But depression in type A’s could also negate some of the mortality risk reducing effects….
Read More »Diabetes In Control
Artificial Sweeteners May Raise Health Risks
People believe that consuming artificial sweetened beverages is better for you but….
Read More »Telmisartan, Valsartan Curb Diabetic Patients’ Heart Risk
When compared to other ARB’s, telmisartan and valsartan are both shown to significantly reduce the risk of hospital admission for stroke, myocardial infarctions, and heart failure by up to 15%….
Read More »Probiotics Could Counter Obesity and Diabetes
Daily ingestion of the VSL#3 commercial probiotic product by mice led to an increase in GLP-1 levels which reduced appetite….
Read More »Amino Acids Predictive of Diabetes and CVD
The amino acids tyrosine, isoleucine, and phenylalanine show a strong predictive nature for….
Read More »Impact of Type 1 Diabetes on Academic Performance
Students with type 1 diabetes were matched with nondiabetic students, and their academic grades in courses such as mathematics, chemistry, biology, physics, English, and humanities compared….
Read More »PubMed Unbound MEDLINE
Unbound Medicine Free iOS/Android Unbound MEDLINE connects you to over 20 million journal citations and abstracts from PubMed via your smartphone. Perform powerful searches and link to the publisher’s full text articles. Visually explore the literature using Grapherence, a unique way to find related and relevant articles.
Read More »Editor’s Note, DCMS #145:
If you look at the notes from the AACE conference, the AAFP conference and the recent ADA Scientific Sessions, you’ll notice a lot of new algorithms for the treatment of diabetes. All this information reminds me of when I was working on improving my golf game. First they told me …
Read More »AACE Comprehensive Diabetes Management Algorithm 2013
The 2013 AACE Comprehensive Diabetes Management Algorithm has quite a few changes including a Prediabetes Algorithm; an Algorithm for Adding/Intensifying Insulin; a CVD Risk Factors Algorithm; and more….
Read More »Roche stops diabetes drug development following safety concerns.
Roche stops diabetes drug development following safety concerns. Roche Holding announced it will cease the development of its diabetes drug aleglitazar after a late-stage trial revealed the medication negatively affects the kidneys and the heart.
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.